TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04860297

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: Sterile liquid for injection
Study: NCT05604417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAZEMETOSTAT
Description: Dosage and treatment timings per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zandelisib
Description: Dosage and treatment timings per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zandelisib
Description: Dosage and treatment timings per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zandelisib
Description: Dosage and treatment timings per protocol
Study: NCT05598697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Skills Building (LSB) curriculum for males
Description: The LSB curriculum offers ten weekly 90-minute sessions. Topics include effective communication, gender roles, power dynamics in the household; work-life balance and time management; conflict resolution; household decision making. The LSB teachers are trained in facilitation techniques to deliver the sessions.~All male study participants attending LSB curriculum classes are married to BISP-CT clients.~For men, the MEWE intervention provides access to the LSB curriculum only.
Study: NCT05485545

Intervention type: OTHER
Group type: OTHER
Intervention: Electrophysiological exploration of the right ventricle
Description: * CARTO electrophysiological mapping system~* 3D echocardiography~* High Resolution MRI

Intervention type: OTHER
Group type: OTHER
Intervention: Electrophysiological exploration of the right ventricle
Description: * CARTO electrophysiological mapping system~* 3D echocardiography~* High Resolution MRI
Study: NCT05598697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Skills Building (LSB) curriculum for females
Description: The LSB curriculum offers ten weekly 90-minute sessions. Topics include effective communication, gender roles, power dynamics in the household; work-life balance and time management; conflict resolution; household decision making. The LSB teachers are trained in facilitation techniques to deliver the sessions.~All female study participants attending LSB curriculum classes are BISP-CT clients.~For females, the MEWE intervention comprises access to LSB curriculum + BISP CTs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Skills Building (LSB) curriculum for females
Description: The LSB curriculum offers ten weekly 90-minute sessions. Topics include effective communication, gender roles, power dynamics in the household; work-life balance and time management; conflict resolution; household decision making. The LSB teachers are trained in facilitation techniques to deliver the sessions.~All female study participants attending LSB curriculum classes are BISP-CT clients.~For females, the MEWE intervention comprises access to LSB curriculum + BISP CTs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash transfer to adult females
Description: The BISP intervention offers access to quarterly unconditional cash transfers to adult females.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash transfer to adult females
Description: The BISP intervention offers access to quarterly unconditional cash transfers to adult females.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cash transfer to adult females
Description: The BISP intervention offers access to quarterly unconditional cash transfers to adult females.
Study: NCT05473845

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupressure intervention
Description: Acupressure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reiki intervention
Description: Reiki
Study: NCT05881811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK16149，probenecid, cimetidine
Description: 40mg HSK16149 single dose, fasted; 500mg probenecid QID from D1\~D4 200mg cimetidine QID from D1\~D4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK16149，probenecid, cimetidine
Description: 40mg HSK16149 single dose, fasted; 500mg probenecid QID from D1\~D4 200mg cimetidine QID from D1\~D4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK16149，probenecid, cimetidine
Description: 40mg HSK16149 single dose, fasted; 500mg probenecid QID from D1\~D4 200mg cimetidine QID from D1\~D4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK16149，probenecid, cimetidine
Description: 40mg HSK16149 single dose, fasted; 500mg probenecid QID from D1\~D4 200mg cimetidine QID from D1\~D4
Study: NCT05516303

Intervention type: GENETIC
Intervention: Genetic polymorphism
Description: One blood tube will be taken for genetic testing

Intervention type: GENETIC
Intervention: Genetic polymorphism
Description: One blood tube will be taken for genetic testing

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of fingolimod and fingolimod-phosphate concentrations
Description: Measurement of fingolimod and fingolimod-phosphate concentrations before usual drug administration time

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of fingolimod and fingolimod-phosphate concentrations
Description: Measurement of fingolimod and fingolimod-phosphate concentrations before usual drug administration time
Study: NCT04836377

Intervention type: OTHER
Intervention: Safety and efficacy assessments
Description: Safety evaluations, disease-specific assessments, and other assessments to monitor for long-term complications of gene therapy intervention
Study: NCT06243445

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic echocardiography for central venous catheter tip location
Description: Measure of time between injection of echographic contrast in the distal lumen of a central venous catheter, inserted via supra/infra clavicular right veins, and visualization, using transthoracic echocardiography, of micro bubbles in right atrium with the catheter tip positioned under transesophageal ultrasound control in four different positions: right atrium, cavo-atrial junction (CAJ), at 4 centimeters proximal to CAJ, in superior vena cava and at 8 centimeters proximal to CAJ
Study: NCT05861908

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Filtek™ Bulk Fill restoration
Description: restoration of class II caries with different bulk-fill technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heated Filtek™ Bulk Fill restoration
Description: restoration of class II caries with different bulk-fill technique
Study: NCT05155176

Intervention type: BEHAVIORAL
Intervention: Intensive Day Monitoring
Description: During intake, a research assistant will demonstrate how to place the HRV monitor, BACtrak Skyn, and provide instructions on completing the saliva samples at home. Participants will wear the HRV and Skyn monitors for three consecutive, randomly selected days twice for individuals with Alcohol Use Disorder and once for social drinkers during the study (72 hours each). Participants will be provided with six saliva sample collection tubes per day with explicit directions on when the saliva sampling should occur (hours since waking: +0, +1, +2, +4, +6, +10 hours, and before going to sleep). Participants will also complete a subjective report using similar questions included in the survey prompts at the same scheduled time as the saliva sample. Individuals with Alcohol Use Disorder would complete a total of 6 such days during the study, and social drinkers would complete a total of 3 such days during the study.

Intervention type: BEHAVIORAL
Intervention: Intensive Day Monitoring
Description: During intake, a research assistant will demonstrate how to place the HRV monitor, BACtrak Skyn, and provide instructions on completing the saliva samples at home. Participants will wear the HRV and Skyn monitors for three consecutive, randomly selected days twice for individuals with Alcohol Use Disorder and once for social drinkers during the study (72 hours each). Participants will be provided with six saliva sample collection tubes per day with explicit directions on when the saliva sampling should occur (hours since waking: +0, +1, +2, +4, +6, +10 hours, and before going to sleep). Participants will also complete a subjective report using similar questions included in the survey prompts at the same scheduled time as the saliva sample. Individuals with Alcohol Use Disorder would complete a total of 6 such days during the study, and social drinkers would complete a total of 3 such days during the study.
Study: NCT05861908

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: G-aenial™ BULK Injectable restoration
Description: restoration of class II caries with different bulk-fill technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sonicfill3 restoration
Description: restoration of class II caries with different bulk-fill technique
Study: NCT06436768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: After the last dose of rocuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was administered.~Dose will be according to participant actual body weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: After the last dose of rocuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine (up to 5 mg maximum dose) plus atropine 0.02 mg/kg (up to 2 mg maximum dose) was administered.~Dose will be according to participant actual body weight.
Study: NCT04611880

Intervention type: DRUG
Group type: OTHER
Intervention: Crizanlizumab
Description: Drug: crizanlizumab is a humanized monoclonal anti-P-selectin antibody that prevents leukocyte adhesion to the vascular endothelium, thereby limiting risk of microvascular occlusion. It is administered intravenously.
Study: NCT05930288

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking exercise
Description: The target physical activity level for participants is to walk 10,000 steps per day and to meet or exceed that level (but not exceed 15,000 steps) seven days a week for three to four weeks. Participants will be advised to gradually increase their daily step count in proportion to their physical condition. Exercise will be performed by brisk walking or jogging using the indoor treadmill equipped by the Neurosurgery Department of Xiangya Hospital or outdoors. Each workout will begin with a 5-minute warm-up and end with a 5-minute cool-down.
Study: NCT06517992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health education for cadre (communicated project)
Description: The investigators perform health education to cadre in order to support their role in providing care for metastatic breast cancer living in the community using a module. The module consists of text (written information) and some videos as education medias.
Study: NCT05370170

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupressure and nutritional advices
Description: Teaching using booklets and application of acupressure
Study: NCT06551857

Intervention type: OTHER
Intervention: Chemotherapy, chemoradiation, radiation therapy
Description: Cancer treatment

Intervention type: OTHER
Intervention: Chemotherapy, chemoradiation, radiation therapy
Description: Cancer treatment

Intervention type: OTHER
Intervention: Chemotherapy, chemoradiation, radiation therapy
Description: Cancer treatment

Intervention type: OTHER
Intervention: Chemotherapy, chemoradiation, radiation therapy
Description: Cancer treatment
Study: NCT05259917

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to KVD900 Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD900 600 mg
Description: KVD900 Tablet 600 mg (2 x 300 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD900 300 mg
Description: KVD900 Tablet 300 mg (1 x 300 mg)
Study: NCT05429840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT1980
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT1980
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT1980
Description: single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose
Study: NCT05622006

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary breaks
Description: Interrupting sitting with different frequencies of walking/jogging at moderate intensity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary breaks
Description: Interrupting sitting with different frequencies of walking/jogging at moderate intensity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary breaks
Description: Interrupting sitting with different frequencies of walking/jogging at moderate intensity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary breaks
Description: Interrupting sitting with different frequencies of walking/jogging at moderate intensity.
Study: NCT03252626

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprostadil
Description: Alprostadil injection USP for intravascular infusion contains 500 micrograms Alprostadil, more commonly known as prostaglandin E1. Vasodilation, inhibition of platelet aggregation are among the most notable of these effects.~2ml Alprostadil injection added into 10ml 0.9% saline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 2ml normal saline injection added into 10ml 0.9% saline.
Study: NCT05066477

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CalGo
Description: CalGo is a natural marine collagenic bone powder from salmon. The bone powder is a 100 % microcrystalline hydroxyapatite form of calcium and phosphorus. Furthermore it contains collagen type 2 and is enriched with vitamin D3.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pure maltodextrin
Study: NCT04682301

Intervention type: BEHAVIORAL
Intervention: Behavioral Intervention
Description: Receive SDM intervention

Intervention type: OTHER
Intervention: Discussion (focus group)
Description: Attend focus group

Intervention type: OTHER
Intervention: Discussion (feedback on SDM)
Description: Provide feedback on SDM

Intervention type: OTHER
Intervention: Interview
Description: Attend a telephone interview

Intervention type: OTHER
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT05046600

Intervention type: DEVICE
Intervention: Products listed in cohort description
Description: Depending on approved indication per product
Study: NCT06477978

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Hand grip function testing
Description: The use of Bio-impedance to measure the skeletal muscle mass
Study: NCT05247762

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The stainless steel needles are used to insert into the two points of Jingming and the Qiuhou, and der-qi, once a week, once for 20 minutes, for 24 consecutive weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: The stainless steel needles are used to insert into the two points of Jingming and the Qiuhou, and der-qi, once a week, once for 20 minutes, for 24 consecutive weeks.
Study: NCT06429241

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells (MSCs)
Description: single dose injection (120 million cells)
Study: NCT04929015

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection - blood and tissue sample collection
Description: The original tissue sample from each patient will be obtained at time of surgery or prior to surgery. Plasma for ctDNA will be obtained at baseline, pre-surgery, post-surgery and every 3 months up 2 years

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Medical record reviewed
Study: NCT05955300

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training program
Description: The GLAD training program consists of neuromuscular exercises for the core, the knee and the hip muscles and patient education. The New Nordic Diet is a plant-based nutrition thats aims to reduce systematic low-grad inflammation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training program
Description: The GLAD training program consists of neuromuscular exercises for the core, the knee and the hip muscles and patient education. The New Nordic Diet is a plant-based nutrition thats aims to reduce systematic low-grad inflammation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition therapy
Description: Nutrition therapy based on the New Nordic Diet
Study: NCT06132438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP-CMV vaccine
Description: The PEP-CMV vaccine is a long synthetic peptide (PEP) made up of 26 amino acids that is derived from the human cytomegalovirus (CMV) matrix protein pp65 and has both MHC class I and II epitopes. A vaccine platform that initially consists of TMZ-induced lymphopenia and Td pre-conditioning will be used, with serial vaccinations of up to 12 times (maximum 20) being applied. To ensure the effectiveness of the future Td pre-conditioning, which is given right before the initial PEP-CMV vaccine, a Td booster is required at enrollment.
Study: NCT06488989

Intervention type: DEVICE
Group type: OTHER
Intervention: left bundle branch area pacing
Description: Cardiac resynchronization therapy obtained by conduction system pacing
Study: NCT05938140

Intervention type: DRUG
Group type: OTHER
Intervention: Nirmatrelvir/ritonavir
Description: Paxlovid is an oral drug for the treatment of COVID-19. It is suitable for adults with mild to moderate COVID-19 patients with high risk factors for progression to severe disease.
Study: NCT06491498

Intervention type: DIAGNOSTIC_TEST
Intervention: Supraclavicular Brachial Plexus Blockade
Description: Hemidiaphragmatic Paralysis Following Ultrasound-Guided Supraclavicular Brachial Plexus Blockade in patients undergoing upper limb surgery

Intervention type: DIAGNOSTIC_TEST
Intervention: Supraclavicular Brachial Plexus Blockade
Description: Hemidiaphragmatic Paralysis Following Ultrasound-Guided Supraclavicular Brachial Plexus Blockade in patients undergoing upper limb surgery
Study: NCT06270134

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bicarbonate
Description: Bicarbonate is added to hemodialysis fluids to correct the metabolic acidosis that arises from kidney failure. Some dialysis units in Canada add bicarbonate to a level of 32 mmol/L, while other units add bicarbonate to a level of 38 mmol/L. It is unknown whether one level is better for people's health.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bicarbonate
Description: Bicarbonate is added to hemodialysis fluids to correct the metabolic acidosis that arises from kidney failure. Some dialysis units in Canada add bicarbonate to a level of 32 mmol/L, while other units add bicarbonate to a level of 38 mmol/L. It is unknown whether one level is better for people's health.
Study: NCT04903301

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contoura Vision LASIK
Description: Topography-Guided LASIK using Phorcides Analytic Software
Study: NCT04835350

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pancreas4ALL - meal announcement or full closed loop
Description: Patient using AID Pancreas4ALL in mode meal announcment or full closed loop.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pancreas4ALL - meal announcement or full closed loop
Description: Patient using AID Pancreas4ALL in mode meal announcment or full closed loop.
Study: NCT06218862

Intervention type: DRUG
Intervention: Sivelestat sodium
Description: Sivelestat sodium was administered through a 24-hour continuous intravenous infusion at a rate of 0.2 mg/kg/h, for at least 72 hours and a maximum duration of 14 days.

Intervention type: DRUG
Intervention: Control
Description: Not use Sivelestat sodium
Study: NCT06356675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg iv D1 Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 12mg D1-12 Q3W
Study: NCT05152719

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Performance
Description: Cognitive function will be measured biweekly 20 minutes after exercise, or at a matched time for the Time Restricted Eating Protocol arm. The Stroop test will be completed on Mondays and the Corsi block test will be completed on Wednesdays. Body composition will be measured on Fridays using a BodPod at baseline, week 3, and week 6.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Performance
Description: Cognitive function will be measured biweekly 20 minutes after exercise, or at a matched time for the Time Restricted Eating Protocol arm. The Stroop test will be completed on Mondays and the Corsi block test will be completed on Wednesdays. Body composition will be measured on Fridays using a BodPod at baseline, week 3, and week 6.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Performance
Description: Cognitive function will be measured biweekly 20 minutes after exercise, or at a matched time for the Time Restricted Eating Protocol arm. The Stroop test will be completed on Mondays and the Corsi block test will be completed on Wednesdays. Body composition will be measured on Fridays using a BodPod at baseline, week 3, and week 6.
Study: NCT05945641

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Load Resistance training
Description: Performing single leg knee extension exercise with using equivalent to \~30%1-RM to failure,

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sprint/High Intensity Interval Training
Description: Performing repeated submaximal/maximal 30second-60 seconds (1-3 minute rest between) aerobic intervals on a Kicking ergometer (modified bike that allows cycling to be performed with one leg using a kicking motion).
Study: NCT05965609

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CBTI
Description: Intervention includes education about sleep and behavioral and cognitive strategies to improve sleep

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MRTI
Description: Intervention includes education about sleep and behavioral and relaxation strategies to improve sleep
Study: NCT05110352

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: A polysmnography is planned for every patients in order to evaluate the Apnea-Hypopnea Index (AHI).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pharyngeal ph-metry Restech
Description: Pharyngeal ph-metry Restech over 24 hours (night and day)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peptest
Description: Saliva sample to look for an association between pharyngolaryngeal reflux and obstructive sleep apnea syndrome

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire RSS-12
Description: Questionnaire with 12 items about quality of life. Score between 0 and 5.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reflux Sign Assessment
Description: RSA score about anatomy and morphology of the mouth